Efficacy of Hyoscine-n-butylbromide in Catheter-related Bladder Discomfort After Elective Cesarean Section.

Overview

a prospective, randomized, placebo-controlled study will be conducted to investigate whether hyoscine-n-butylbromide has preventive effects on early postoperative CRBD in patients with urinary catheters who will undergo elective cesarean sections.

Full Title of Study: “Efficacy and Safety of Hyoscine-n-butylbromide for the Alleviation of Early Catheter-related Bladder Discomfort After Elective Cesarean Delivery: a Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: July 1, 2020

Detailed Description

The insertion of a urinary catheter in a patient undergoing a surgical procedure as cesarean section may lead to catheter-related bladder discomfort with varying degrees of severity during the postoperative period. Catheter-related bladder discomfort (CRBD) symptoms associated with an indwelling urinary catheter are similar to overactive bladder symptoms such as discomfort in the suprapubic region, urinary urgency, frequency, burning sensation with or without urge incontinence. Hyoscine N-butyl bromide also known as scopolamine is a drug with anticholinergic effects which exerts its effects by inhibiting the acetylcholine effects in parasympathetic receptors of smooth muscle cells, secretory glands, and central nervous system. Hyoscine-n-butylbromide was reported to be effective for treatment of CRBD. More preventive than therapeutic drugs for CRBD should be investigated to improve patient comfort in all surgery patients with a urinary catheter. A prospective, randomized, placebo-controlled study will be conducted to investigate whether hyoscine-n-butylbromide has preventive effects on early postoperative CRBD in patients with urinary catheters who will undergo elective cesarean sections.

Interventions

  • Drug: hyoscine-n-butylbromide
    • one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
  • Drug: control group
    • an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.

Arms, Groups and Cohorts

  • Experimental: hyoscine-n-butylbromide group
    • one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
  • Placebo Comparator: control group
    • the same volume (1 ml) of normal saline intravenously immediately before the end of the cesarean section.

Clinical Trial Outcome Measures

Primary Measures

  • catheter related bladder discomfort(CRBD) measured by numerical rating scale(NRS).
    • Time Frame: one hour post-operatively.
    • the incidence and severity of CRBD between the 2 groups will be assessed by the 11-point numerical rating scale which is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of her pain.The 11-point numeric scale ranges from ‘0’ representing one pain extreme (e.g. “no pain”) to ’10’ representing the other pain extreme (e.g. “pain as bad as you can imagine” or “worst pain imaginable”). CRBD will be defined as the presence of an urge to void or suprapubic discomfort with an NRS score of ≥3.

Secondary Measures

  • catheter related bladder discomfort(CRBD) measured by numerical rating scale(NRS).
    • Time Frame: two hours postopeatively.
    • the incidence and severity of CRBD between the 2 groups will be assessed by the 11-point numerical rating scale which is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of her pain.The 11-point numeric scale ranges from ‘0’ representing one pain extreme (e.g. “no pain”) to ’10’ representing the other pain extreme (e.g. “pain as bad as you can imagine” or “worst pain imaginable”).
  • catheter related bladder discomfort(CRBD) measured by numerical rating scale(NRS).
    • Time Frame: six hours postoperatively.
    • numerical rating scale.
  • Postoperative nausea and vomiting
    • Time Frame: 6 hours postoperative
    • Postoperative nausea and vomiting
  • dry mouth
    • Time Frame: 6 hours postoperative
    • the patient says”My mouth is dry”
  • facial flushing
    • Time Frame: 6 hours postoperative
    • My face is hot.
  • painkiller
    • Time Frame: Up to 6 hours after study drug administration
    • the need for rescue analgesics

Participating in This Clinical Trial

Inclusion Criteria

  • Elective primary or repeat cesarean section at or more than 38 weeks of gestation scheduled to insert a Foley catheter in the operation site. Exclusion Criteria:

  • • Urinary infection (assessed clinically and by urinalysis of midstream sample of urine (MSSU) with chemical indicator strips or dipsticks). – Contraindications for general anesthesia. – Maternal bladder, urethral and renal disorders causing irritating voiding problems such as dysuria, urge and stress incontinence. – Obstructive voiding symptoms like incomplete emptying, straining and voiding difficulty before surgery. – Overactive bladder (frequency: more than three times during the night or more than eight times in 24 h). – Morbid obesity. – Disturbances of the central nervous system (epilepsy, patients receiving MAO inhibitor). – Hypertensive disorders and/ or systemic disease requiring particular patient care (for example, cardiac disease, nephritic disorders). – Chronic analgesic abuse. – Hepatic or psychiatric disease will be excluded from the study. – A history of hypersensitivity or contraindication to hyoscine-n-butylbromide.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Cairo University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ahmed Samy aly ashour, lecturer in obstetrics and gynecology – Cairo University
  • Overall Official(s)
    • AHMED SAMY, MD, Principal Investigator, Cairo University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.